Background In 1998, a new intragastric balloon for the treatment of obesity was introduced into clinical practice. It corresponded fully to the requisites of the Consensus Conference held at Tarpon Springs (Florida, USA) in 1987. Purpose The aim of the study was to analyze the outcome of a 5-year experience, using the BioEnterics® intragastric balloon for the treatment of morbid obesity. Methods Between March 1998 and January 2003 we endoscopically inserted 349 BioEnterics® intragastric balloons (BIB) in 303 patients affected with I-II degree obesity and morbid obesity. There were 95 were males and 208 females; mean age was 41.5 years (range: 19-70), mean weight was 118.8 kg (range: 67-229) and mean body mass index (BMI) was 42.0 kg./m2 (range: 29-81). A balanced diet of 1,000 calories/day was associated with balloon treatment, along with the temporary use of antisecretory drugs. Follow-up consisted of a check-up with a dietician every two weeks and surgical monitoring once a month. Results Mean weight loss was 13.5 kg. and mean BMI loss 4.9 kg/m2. Weight loss was greatest in morbidly obese males (BMI > 40). The main complications encountered were: intolerance, balloon rupture, and gastric erosion. Conclusions Our experience demonstrated that treatment with the BIB is particularly suitable: a) for morbidly obese and superobese subjects to reduce surgical risk in bariatric surgery; b) for obese subjects with BMI > 35 who have complications associated with obesity; c) for overweight subjects, exclusively in the context of multidisciplinary therapy.
Another option for treating morbid obesity: the intragastric balloon
Canavese F;
2003-01-01
Abstract
Background In 1998, a new intragastric balloon for the treatment of obesity was introduced into clinical practice. It corresponded fully to the requisites of the Consensus Conference held at Tarpon Springs (Florida, USA) in 1987. Purpose The aim of the study was to analyze the outcome of a 5-year experience, using the BioEnterics® intragastric balloon for the treatment of morbid obesity. Methods Between March 1998 and January 2003 we endoscopically inserted 349 BioEnterics® intragastric balloons (BIB) in 303 patients affected with I-II degree obesity and morbid obesity. There were 95 were males and 208 females; mean age was 41.5 years (range: 19-70), mean weight was 118.8 kg (range: 67-229) and mean body mass index (BMI) was 42.0 kg./m2 (range: 29-81). A balanced diet of 1,000 calories/day was associated with balloon treatment, along with the temporary use of antisecretory drugs. Follow-up consisted of a check-up with a dietician every two weeks and surgical monitoring once a month. Results Mean weight loss was 13.5 kg. and mean BMI loss 4.9 kg/m2. Weight loss was greatest in morbidly obese males (BMI > 40). The main complications encountered were: intolerance, balloon rupture, and gastric erosion. Conclusions Our experience demonstrated that treatment with the BIB is particularly suitable: a) for morbidly obese and superobese subjects to reduce surgical risk in bariatric surgery; b) for obese subjects with BMI > 35 who have complications associated with obesity; c) for overweight subjects, exclusively in the context of multidisciplinary therapy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
